Science · Open for opinions
Will a phase 2 clinical trial for in vivo cell therapy against multiple sclerosis be registered on ClinicalTrials.gov by 10/31/2026?
Consider records of new clinical studies between 09/06 and 10/31 after positive early-phase results published in Nature. 15 opinions, 60% No
- Yes — 40%
- No — 60%
Deadline: October 31, 2026 at 11:59 PM UTC · 15 opinions
Resolution rules
Consider records of new clinical studies between 09/06 and 10/31 after positive early-phase results published in Nature.
Source: www.nature.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 06/09/2026 (00:00, horário de Brasília) até 31/10/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se um protocolo de ensaio clínico de Fase 2 avaliando terapia celular/vetorial in vivo para esclerose múltipla for formalmente indexado na base pública ClinicalTrials.gov (NIH) até 31/10/2026. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 60% of the votes: an opinion on it that turns out right earns about 40 points, a wrong one costs about 60.